Rebound-associated vertebral fractures after denosumab discontinuation in a lung cancer patient with bone metastases

Jolan Dupont; Wesley Appermans; Marian Dejaeger; Isabelle Wauters; Michaël R Laurent; Evelien Gielen

doi:10.1016/j.bonr.2022.101582

Rebound-associated vertebral fractures after denosumab discontinuation in a lung cancer patient with bone metastases

Bone Rep. 2022 May 4:16:101582. doi: 10.1016/j.bonr.2022.101582. eCollection 2022 Jun.

Authors

Jolan Dupont^{1

2

3}, Wesley Appermans², Marian Dejaeger^{1

2

3}, Isabelle Wauters⁴, Michaël R Laurent^{3

5}, Evelien Gielen^{1

2

3}

Affiliations

¹ Geriatrics and Gerontology, Department of Public Health and Primary Care, KU Leuven, Leuven, Belgium.
² Department of Geriatric Medicine, UZ Leuven, Leuven, Belgium.
³ Centre for Metabolic Bone Diseases, UZ Leuven, Leuven, Belgium.
⁴ Department of Respiratory Medicine, UZ Leuven, Leuven, Belgium.
⁵ Imelda Hospital, Bonheiden, Belgium.

Abstract

Denosumab is a commonly used antiresorptive treatment in patients with osteoporosis or solid tumours with bone metastases. Upon denosumab discontinuation, a rebound phenomenon can occur that results in an increased (vertebral) fracture risk. This phenomenon is well-known in the setting of osteoporosis but rarely reported in cancer patients with bone metastases discontinuing denosumab. We present the case of a 43-year old women with lung cancer and bone metastases who suffered multiple vertebral fractures after discontinuation of denosumab.

Keywords: Bone turnover markers; Denosumab; Osteoporosis; Rebound phenomenon; Vertebral fractures.

Publication types

Case Reports